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Summary
The HDM2 protein plays an important role in regulating the stability and function of the p53 tumor suppressor protein. In
this report, we show that the ribosomal protein L11 can interact with HDM2 and inhibit HDM2 function, thus leading to
the stabilization and activation of p53. The inhibition of HDM2 activity by L11 shows some similarity to the previously
described activity of ARF, and expression of either ARF or L11 can induce a p53 response. Enhancement of the interaction
between endogenous L11 and HDM2 following treatment of cells with low levels of actinomycin-D suggests that the HDM2/
L11 interaction represents a novel pathway for p53 stabilization in response to perturbations in ribosome biogenesis.
Introduction et al., 1992; Oliner et al., 1993; Wadgaonkar and Collins, 1999).
The ubiquitination of p53 by HDM2 contributes to the proteaso-
mal degradation of p53 and also to the export of p53 from theThe p53 tumor suppressor protein is a potent inhibitor of cell
growth, inducing cell cycle arrest and apoptosis (reviewed in nucleus to the cytoplasm (Boyd et al., 2000; Geyer et al., 2000;
Gu et al., 2001; Haupt et al., 1997; Kubbutat et al., 1997; LohrumVousden, 2000). Although p53 function is not absolutely re-
quired for normal growth and development, p53 plays an impor- et al., 2001). p53 is a transcription factor that induces expression
of many genes that mediate the apoptotic and cell cycle arresttant role in preventing tumor development. p53 function, which
is kept tightly regulated in normal cells, is rapidly induced in response to p53 induction (Vousden and Lu, 2002). Importantly,
p53 can also activate transcription of HDM2, establishing aresponse to many kinds of stress signals (Ryan et al., 2001).
This activation of p53 leads to inhibition of cell growth in cells regulatory loop in which p53 induces expression of its own
negative regulator (Barak et al., 1993; Wu et al., 1993). Theundergoing oncogenic changes, and combined with a direct
contribution of p53 in allowing repair of DNA damage, plays a importance of the p53/HDM2 regulatory loop in allowing normal
development has been demonstrated in mice, where loss ofcritical role in preventing tumor development. The importance
of p53 in tumor suppression is illustrated by the observation Mdm2 results in early embryonic lethality that is the conse-
quence of p53-mediated apoptosis (de Rozieres et al., 2000;that around half of all human cancers have lost p53 activity
through mutation within the p53 gene, while many others show Jones et al., 1995; Montes de Oca Luna et al., 1995). Deletion
of p53 with Mdm2 rescues the lethal phenotype, allowing p53/defects in the ability to activate or respond to p53. Taken to-
gether, it is apparent that most, if not all, cancers are defective Mdm2 double null mice to develop essentially normally.
Stress-induced activation of p53 depends in part on thein the normal p53 response.
The murine double minute 2 protein (Mdm2 or HDM2 in inactivation of HDM2 and the inhibition of HDM2-mediated ubi-
quitination of the p53 protein. The inhibition of HDM2 can behuman) was originally described in transformed mouse cells
and shown to have oncogenic activity (Fakharzadeh et al., 1991), achieved through several mechanisms, with different stress sig-
nals utilizing different pathways to allow stabilization of p53and HDM2 is found to be amplified in some human sarcomas
(Oliner et al., 1992). The best understood function of HDM2 is (Ashcroft et al., 2000). DNA damage-induced phosphorylation
of p53 or HDM2, for example, has been shown to regulate theits ability to negatively regulate p53, both by directly binding to
p53 and through its activity as an E3 ligase that can target p53 formation of the p53/HDM2 complex or the ability of HDM2 to
target p53 for degradation (Blattner et al., 2002; Buschmann etfor ubiquitination (Fang et al., 2000; Honda et al., 1997; Momand
S I G N I F I C A N C E
The p53 tumor suppressor protein is activated by several cellular stress signals associated with tumor development. Activation of
p53 is accompanied by stabilization of the p53 protein following inhibition of HDM2, the ubiquitin ligase for p53. We show here that
the ribosomal protein L11 can interact with HDM2 and inhibit the degradation of p53, and provide evidence that the HDM2/L11
interaction is enhanced in response to perturbations in ribosome biogenesis. This process is sensitive to abnormalities in metabolism
and growth - conditions that may exist during tumor progression. Our results therefore identify a novel pathway for p53 induction
under these conditions and provide a target for the design of drugs to reactivate p53.
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al., 2001; Chehab et al., 2000; Goldberg et al., 2002; Hirao et
al., 2000; Maya et al., 2001; Shieh et al., 2000). HDM2 activity
can also be regulated by interaction with other proteins. The
small ARF protein binds to HDM2 and inhibits HDM2s ability to
target p53 for degradation (Pomerantz et al., 1998; Stott et al.,
1998; Zhang et al., 1998). This function of ARF is important in
activating a p53 response to abnormal proliferation driven by
activation of oncogenes such as Myc and Ras (Sherr and Weber,
2000), although ARF does not seem to be required for the stabili-
zation of p53 in response to other types of stress (Ashcroft et
al., 2000; Khan et al., 2000).
Although the interaction of ARF with HDM2 can directly
inhibit HDM2’s E3 activity (Honda and Yasuda, 1999; Midgley
et al., 2000), the interaction of HDM2 and ARF can also result
in relocalization of HDM2 to the nucleolus (Lohrum et al., 2000;
Rizos et al., 2000; Weber et al., 1999, 2000). This relocalization
of HDM2 is not essential for the inhibition of HDM2 function by
ARF in all cells (Korgaonkar et al., 2002; Llanos et al., 2001),
but it seems likely that sequestration of HDM2 may contribute
to the inactivation of HDM2 under some conditions. Nucleolar
localization of HDM2 in response to ARF depends on a nucleolar
localization signal within HDM2 itself (Lohrum et al., 2000; Weber
et al., 2000), leading to the suggestion that other signals may
also affect HDM2 function by driving nucleolar localization of
HDM2. Interestingly, ARF-independent colocalization of HDM2
with nucleolar proteins has also been seen during the stabiliza-
tion of p53 following treatment of cells with low levels of actino-
mycin-D or proteasome inhibitors (Ashcroft et al., 2000; Xirodi-
mas et al., 2001). Previous studies have described an interaction
of HDM2 with a ribosomal protein L5 and ribosomal RNA (Mare-
chal et al., 1994), and it is possible that interactions with compo-
nents of the ribosome may contribute to the localization and/or
retention of HDM2 to the nucleolus.
In this study, we describe a novel interaction between HDM2
and the ribosomal L11 protein. Interaction with L11 can lead to
nucleolar localization of HDM2, which is dependent on the NoLS
in the C terminus of HDM2. Like ARF, L11 inhibits the ability of
HDM2 to degrade p53 and expression of L11 induces a p53
response. The interaction between HDM2 and L11 is enhanced Figure 1. Association of L11 with HDM2
in response to treatment with low levels of actinomycin-D, which A: Cartoon of the HDM2 protein, indicating the position of principal domains.
selectively inhibit the activity of RNA polymerase I. Our results B: Coprecipitation of the indicated HDM2 proteins with p53 following trans-
fection into U2OS cells. Twenty-four hours posttransfection, the cells weretherefore suggest that L11 may play a role in the inactivation
lysed and p53 immunoprecipitated using the monoclonal antibody DO-1.of HDM2 and induction of the p53 in response to perturbations
Associated HDM2 protein was detected by Western blotting using AB1in ribosomal synthesis or assembly. and AB2.
C: Coprecipitation of the indicated HDM2 proteins with L11 following trans-
fection into U2OS cells as described above. L11 protein was immunoprecipi-Results
tated through the Flag-tag.
D: Expression of the indicated HDM2 proteins following transfection intoInteraction of HDM2 with L11
U2OS cells.
Using a fragment of HDM2 encompassing amino acids 210–491 E: Coprecipitation of the indicated HDM2 proteins with L11 following cotran-
as bait, we carried out a yeast two-hybrid screen to identify sfection into U2OS cells. L11 protein was immunoprecipitated through the
Flag-tag.HDM2-interacting proteins. One of the interacting clones identi-
fied in this way encoded the ribosomal L11 protein. The interac-
tion between HDM2 and L11 was confirmed by coprecipitation
of the two proteins following transient overexpression in U2OS
able to coprecipitate wild-type HDM2 and HDMAla464,cells (Figure 1) and in vitro translation (Figure 3). HDM2 has
HMD2222-437 was defective in the interaction with L11 (Figurebeen shown to bind to p53 through an N-terminal domain, and
1C). These results demonstrated that p53 and L11 bound towe confirmed that p53 could form a complex with wild-type
different regions on HDM2. Further analysis of mutations withinHDM2, an HDM2 protein carrying a point mutation in the
the central region of HDM2 showed that deletion of the regionC-terminal RING finger (HDM2Ala464) and an HDM2 protein
between amino acids 212–347 significantly reduced the bindingdeleted of the central region (HDM2222–437) (Figure 1B) (Kub-
butat et al., 1999). By contrast, although Flag-tagged L11 was between L11 and HDM2, although deletion of amino acids 295–
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Figure 2. Interaction of L11 with HDM2 is en-
hanced in response to actinomycin-D
A: Coprecipitation of endogenous HDM2 with
endogenous L11 from RKO cells. Cells were
treated with 20 M MG132 (Calbiochem) for 6
hr, with addition of the indicated concentrations
of actinomycin-D for the final 2 hr. L11 was immu-
noprecipitated using polyclonal anti-L11 antise-
rum. Coprecipitated HDM2 proteins were de-
tected by Western blotting using a mixture of AB1
and AB2. Western blots were also carried out to
show total levels of HDM2 and L11 in each lysate.
B: Coprecipitation of endogenous HDM2 with
endogenous L11 from untransformed human ret-
inal pigment epithelial cells treated with MG132
for 6 hr, with the addition of 5 nM actinomycin-D
for the indicated times. Immunoprecipitations
were carried out as above.
C: Coprecipitation of endogenous HDM2 with
endogenous L11 from RKO cells treated with
MG132 for 6 hr, with the addition of actinomy-
cin-D or exposure to UV after 4 hr. Immunopre-
cipitations and Western blotting were carried out
as above.
417 or 296–346 did not prevent the interaction (Figures 1D and we were able to detect an interaction between these in-
creased levels of endogenous HDM2 and L11 in RKO, RPE,and 1E). A similar region of HDM2 is required for ARF binding
(Bothner et al., 2001). U2OS, and MCF-7 cells (data not shown).
Our results indicated that although the interaction betweenTo determine whether endogenous L11 and HDM2 could
form an association, we raised a rabbit polyclonal antibody endogenous HDM2 and L11 was not easily seen in unstressed
cells, a detectable interaction could form when HDM2 levelsagainst a C-terminal L11 peptide and examined lysates from
MCF-7 and RKO cells. Immunoprecipitation of L11 showed no were increased by proteasome inhibition—which has also been
shown to allow nucleolar accumulation of HDM2 (Xirodimas etclear evidence of association with HDM2, although this may
reflect difficulties in detection since in unstressed cells HDM2 al., 2001). We therefore considered the possibility that the
HDM2/L11 interaction might be enhanced in response to stress.is a rapidly degraded protein and so is expressed at relatively
low levels. Therefore, in order to increase the overall levels of Treatment of cells with low levels of actinomycin-D has pre-
viously been shown to stabilize p53 without phosphorylation ofHDM2, we treated the cells with the proteasome inhibitor
MG132 (to stabilize the HDM2 protein). Although this treatment p53 or downregulation of HDM2 (Ashcroft et al., 2000), and we
found that treatment of RKO cells with actinomycin-D led to andid not increase the levels of L11, HDM2 levels were enhanced
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lysates by ethidium bromide staining and this was efficiently
digested by treatment with RNase (Figure 3A). However, the
RNase treatment had no effect on the coprecipitation of HDM2
by L11 (Figure 3B), suggesting that the HDM2/L11 interaction
is not mediated by RNA.
L11 stabilizes both HDM2 and p53
Both L11 and ARF bind within the central region of HDM2 (Stott
et al., 1998). Since ARF has been shown to inhibit HDM2 ubiqui-
tin ligase function, preventing HDM2-mediated degradation of
both itself and p53, we considered the possibility that L11 might
have the same effect. Coexpression of L11 with HDM2 and p53
prevented degradation of p53 in a manner analogous to that
seen following ARF expression (Figure 4A). Expression of L11
also resulted in stabilization of HDM2, once again showing simi-
larity to the previously described effect of ARF (Figure 4B).
Furthermore, in U2OS cells, which express wild-type p53 and
HDM2, but no ARF, elevation of endogenous p53 and HDM2
Figure 3. The HDM2/L11 interaction is not mediated by RNA
levels was seen following L11 expression (Figure 4C). Taken
A: Ethidium bromide stained agarose gel showing the effect of RNase treat- together, these results suggest that the interaction of L11 with
ment of rabbit reticulocyte lysates containing in vitro translated HDM2
HDM2 inhibits the ability of HDM2 to target both p53 and itselfand L11.
for ubiquitination and degradation.B: Coprecipitation of HDM2 with L11 expressed in reticulocyte lystates with
or without RNase treatment. The indicated 35S-labeled proteins were al- We next examined whether the overexpression of HDM2
lowed to associate, then L11 immunoprecipitated through the Flag-tag. could result in degradation of L11, like p53. Although ARF is
L11 and associated HDM2 proteins were visualized by autoradiography.
not degraded by HDM2, the ARF protein does not contain lysine
residues for ubiquitination. However, although L11 does contain
lysines, under conditions where HDM2 clearly leads to the deg-
radation of p53, no degradation of L11 was observed (Fig-increase in the amount of HDM2 coprecipitated with L11 (data
ure 4D).not shown). However, although L11 levels were not affected by
Although HDM2 plays a major role in regulation of p53 turn-actinomycin-D treatment, HDM2 levels did increase (possibly
over, other mechanisms that can contribute to the stability of
in response to activation of p53), and so we sought to distinguish
p53 have also been described (reviewed in Woods and Vousden,
enhanced HDM2/L11 binding from an increase in the overall
2001). While L11 could inhibit p53 degradation targeted by co-
levels of available HDM2 by first stabilizing HDM2 and then
transfected HDM2, L11 expression had no effect on the stability
exposing the cell to actinomycin-D. Using this approach, we of a p53 mutant that lacks the HDM2 binding site and is not
found that the HDM2/L11 interaction seen following MG132 degraded by HDM2 (data not shown), supporting a role for L11
treatment was significantly enhanced following treatment of in the abrogation of HDM2-mediated degradation of p53. We
cells with low levels of actinomycin-D that would inhibit RNA noted that expression of L11 could stabilize wild-type p53 in
polymerase I, but have less effect on the activity of RNA poly- U2OS cells beyond levels seen in the absence of exogenous
merase II or III (Perry and Kelley, 1970). The increase in HDM2/ HDM2 (Figure 4A), possibly reflecting inhibition of the endoge-
L11 interaction was seen within 2 hr in both the RKO tumor cell nous HDM2 in these cells. To clarify the role of HMD2 in mediat-
line (Figure 2A) and untransformed human epithelial cells (Figure ing the effect of L11 on p53 levels, we examined the activity of
2B). To test whether the enhancement of the interaction between L11 in mouse embryo fibroblasts lacking endogenous Mdm2
L11 and HDM2 was a general consequence of genotoxic stress, and p53 (Figure 4E). In these cells, L11 also inhibited the ability
we compared the effect of actinomycin-D treatment with UV of exogenous HDM2 to degrade transfected p53. In the absence
treatment of RKO cells (Figure 2C) and RPE cells (data not of HDM2, we reproducibly noted a very slight increase in p53
shown). In each case, only actinomycin-D treatment resulted in levels following expression of L11, raising the possibility that
a significant increase in the HDM2/L11 interaction. Interestingly, L11 may function to target an additional, unidentified regulator
UV has been shown to induce the ribotoxic stress response of p53 stability, such as the recently identified ubiquitin ligase
(Iordanov et al., 1998), which interferes specifically with transla- Pirh2 (Leng et al., 2003).
tional elongation. Although it is possible that longer or more
severe UV treatment would induce increased HDM2/L11 bind- Colocalization of HDM2 and L11
ing, our results suggest that the enhancement of the L11/MDM2 Both L11 and ARF are nucleolar proteins and under some condi-
interaction shows some specificity to stress signals that can tions, expression of ARF has been shown to result in the relocal-
affect ribosome synthesis or assembly. ization of HDM2 to nucleoli (Weber et al., 1999). We therefore
Previous studies have shown that HDM2 can interact directly investigated the possibility that L11 can also relocalize HDM2.
with rRNA, and we therefore sought to determine whether the Initial experiments were carried out by cotransfecting L11 and
HDM2/L11 interaction is mediated by RNA. In order to address HDM2 into U2OS cells. Expression of HDM2 alone in these
this point, we examined the interaction of in vitro translated L11 cells resulted in localization of HDM2 in the nucleoplasm, with
and HDM2 before or after treatment of the lysates with RNase occasional cytoplasmic staining, while L11 expressed alone was
found to be localized to the nucleolus, with overall staining(Figure 3). Significant amounts of RNA could be detected in the
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Figure 4. L11 inhibits HDM2-mediated degradation of p53
A: Stabilization of transfected p53. The Western blot shows expression of Flag-p53, HDM2, L11, and ARF following transient cotransfection of the indicated
plasmids into U2OS cells. HDM2 expression leads to the degradation of p53, which is inhibited by either L11 or ARF expression. Equal amounts of GFP were
added to each transfection to control for transfection efficiency and loading.
B: Stabilization of transfected HDM2. The Western blot shows expression of transfected HDM2 and L11 in transiently transfected U2OS cells. Equal amounts
of HDM2 were included in each transfection with increasing amounts of L11. Equal amounts of GFP were added to each transfection to control for
transfection efficiency and loading.
C: Stabilization of endogenous HDM2 and p53. The Western blot shows the effect of increasing amounts of transfected L11 on the levels of endogenous
HDM2 and p53 in U2OS cells.
D: HDM2 expression leads to the degradation of p53, but not L11. Levels of HDM2, Flag-p53, and L11 protein were detected by Western blot following
transient cotransfection of equal amounts of p53 or L11, with increasing amounts of HDM2.
E: HDM2 dependence of the stabilization of p53 by L11. The Western blot shows expression of p53 and L11 following transient cotransfection of p53, HDM2,
and increasing levels of L11, as indicated, into p53/Mdm2 double null mouse embryo fibroblasts.
throughout the cell in cases of high L11 expression levels (Figure Previous studies examining relocalization of HDM2 to the
nucleoli with ARF defined HMD2 mutants that have lost the5A). When transfected alone, nucleolar HDM2 was detected in
less than 1% of the cells. Following coexpression of L11 and HDM2 NoLS and fail to relocalize (Lohrum et al., 2000; Weber
et al., 2000). Coexpression of HDM2 1-440, which has lost theHDM2, we were able to detect colocalization of the two proteins
in the nucleolus in those cells showing nucleolar localization of NoLS but retains the ability to bind L11 (data not shown), did
not relocalize to the nucleolus with L11, and L11 in this caseL11. Titration experiments showed that this result was depen-
dent on the relative levels of L11 and HDM2; at low L11 concen- is also nucleoplasmic rather than nucleolar (Figure 6A). This
observation suggests that the NoLS in HDM2 contributes to thetrations, both proteins remained in the nucleoplasm while at
higher levels of L11 expression, both proteins relocalized to the relocalization of the protein by L11, as it does to the relocaliza-
tion of HDM2 by ARF (Lohrum et al., 2000). The HDM2222-nucleolus. Under these conditions, nucleolar HDM2 could be
detected in up to 90% of cells cotransfected with L11 and 437 mutant, as previously described, is constitutively nucleolar,
and under these conditions, L11 is also nucleolar. To testHDM2. We also found that ectopic expression of L11 in U2OS
cells can result in relocalization of endogenous HDM2 to the whether binding of L11 to HDM2 is required for the relocaliza-
tion, we examined some of the smaller HDM2 deletion mutantsnucleolus (Figure 5B), although this was not seen in all cells in
the population. shown in Figure 1D. Both HDM2296-346 and HDM2212-347
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Figure 5. Subcellular localization of HDM2 and L11
A: Subcellular localization of transfected L11 and HDM2 in U2OS cells. When expressed alone, L11 is predominantly nucleolar and HDM2 confined to the
nucleoplasm. Twenty-four hours after cotransfection, L11 and HDM2 are both localized to the nucleoplasm, when the L11:HDM2 ration is low (2:1), or both
localized to the nucleolus when L11 levels are higher (4:1).
B: Relocalization of endogenous HDM2 to the nucleolus following transfection of L11 in U2OS cells. Twenty-four hours after transfection of L11 into U2OS
cells, nucleolar localization of endogenous HDM2 is seen in around 40% of the L11-expressing cells.
localized to the nucleoplasm in the absence of cotransfected though nucleoli appear to remain at least partially intact in the
presence of very low levels of actinomycin-D, previous studiesL11 (Figure 6B). Upon coexpression of L11, the HDM2296-
346 mutant, which retains binding to L11 (Figure 1E), was relo- have shown that higher concentrations of actinomycin-D can
result in the release of some components of the nucleolus intocalized to the nucleolus (Figure 6B). However, HDM2212-347,
which is defective for L11 binding (Figure 1E), was significantly the nucleoplasm (Yokoyama et al., 1992). To determine whether
L11 and HDM2 remain colocalized under such conditions, weless efficiently relocalized to the nucleolus with L11 (Figure 6B),
although a small proportion of the cotransfected cells still examined the localization of both L11 and HDM2 in cells treated
with concentrations of actinomycin-D sufficient to release theshowed some evidence of nucleolar HDM2. These results sup-
port a role for the binding of HDM2 to L11 in allowing relocaliza- B23 proteins from the distinctive nucleolar location within 7 hr
of treatment (Figure 7). Immediately after treatment with actino-tion or retention of HDM2 in the nucleolus.
The ability of ectopic L11 to drive HDM2 to the nucleolus mycin-D, where nucleolar structure remains intact as measured
by B23 localization, both L11 and HDM2 colocalized with B23suggested that L11 may play a role in relocalizing HDM2 in the
absence of ARF. We previously showed that treatment of cells to discrete subnuclear bodies. However, after longer treatment
(Figure 7), or at higher actinomycin-D concentrations (data notwith low concentrations of actinomycin-D could result in relocal-
ization of HDM2 to distinct nuclear locations also occupied by shown), both L11 and HDM2 were found to be colocalized with
B23 in the nucleoplasm (Figure 7). Taken together, these resultsthe nucleolar protein B23, even in cells lacking ARF (Ashcroft
et al., 2000). In light of the results presented here, it is possible suggest that the HDM2/L11 complex could be formed in both
the nucleolus and the nucleoplasm, like the ARF/HDM2 com-that this relocalization reflects the activation of the HDM2/L11
interaction following actinomycin-D treatment (Figure 2). Al- plex.
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Figure 6. Relocalization of HDM2 to the nucleolus by L11 depends on the NoLS in HDM2 and binding of L11 to HDM2
A: Subcellular localization of wild-type HDM2, HDM2 1–440 (containing only amino acids 1–440 and therefore lacking the NoLS), and HDM2222–437 (lacking
amino acids 222–437). In the absence of cotransfected L11, wild-type HDM2 and HDM2 1–440 are localized to the nucleoplasm, while HDM2222–437 is
constitutively localized to the nucleoli, as previously described (Lohrum et al., 2000). Wild-type HDM2 relocalizes to the nucleolus following L11 expression,
while HDM2 1–440 remains nucleoplasmic. HDM2 1–440 also causes relocalization of L11 to the nucleoplasm.
B: Subcellular localization HDM2296–346 (that retains the ability to bind L11) and HDM2212–347 (with reduced L11 binding activity) in the absence and
presence of coexpressed L11.
L11 activates p53-dependent cell cycle arrest
The ability of L11 to bind HDM2 and allow stabilization of p53
suggests that L11 may be able to participate in a signaling
pathway that has been shown to induce a p53 response follow-
ing nucleolar stress (Pestov et al., 2001). We therefore examined
whether L11 could signal to activate p53-dependent cell cycle
arrest. Transfection of L11 into ARF null U2OS cells led to stabili-
zation of the endogenous p53 (Figure 4), and flow cytometric
analysis of these transfected cells showed that expression of
L11 and stabilization of p53 led to a G1 arrest similar to that
seen following transfection of ARF (Figure 8A). To demonstrate
that this arrest was the result of p53 activation, we examined
the effect of coexpression of E6, a human papillomavirus protein
that targets p53 for degradation and inhibits the p53 response
(Vousden, 1995). As shown previously for ARF (Stott et al.,
1998), E6-mediated inhibition of p53 markedly decreased the
induction of the G1 arrest in response to L11 (Figure 8B), indicat-
Figure 7. Subcellular localization of L11 and HDM2 in response to actinomy- ing that the stabilization of p53 by L11 correlates with an activa-
cin-D
tion of p53-dependent cell cycle arrest. These results are consis-
U2OS cells were transfected with L11 and HDM2 at a ratio of 4:1 and treated tent with the previously described ability of actinomycin-D to
with 10 nM actinomycin-D for the indicated times. Localization of each
stabilize p53 and induce cell cycle arrest in wild-type p53-transfected protein was then compared to the localization of endogenous
B23, a nucleolar protein. expressing cells (Nelson and Kastan, 1994). For example, treat-
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Figure 8. L11 activates p53 function
A: L11 and ARF activate endogenous p53 to in-
duce cell cycle arrest. Expression of L11 increases
endogenous p53 levels in U2OS cells (Figure 4),
resulting in an elevation of the number of cells
in the G1 phase of the cell cycle, as measured
by flow cytometric analysis of transfected cells.
The graph shows the percentage increase in G1
cells compared to vector only transfected cells
as control (C) following expression of increasing
amounts of L11 or ARF.
B: The G1 arrest induced by L11 is p53 depen-
dent. U2OS cells were transfected with vector
or L11 in the absence or presence of E6, which
targets p53 for degradation and inhibits activa-
tion of a p53-dependent response. The graph
shows the percent of the transfected cell popu-
lation in G1, compared to vector only controls
(C). Western blotting confirmed a reduction in
p53 levels in the E6-expressing cells (data not
shown).
ment of the U2OS cells used in Figure 8 with 5 nM actinomy- levels of actinomycin-D to signal stabilization of p53 does not
require ARF nor the efficient N-terminal phosphorylation of p53cin-D for 24 hr led to a 59% increase in the G1 population.
(Ashcroft et al., 2000), although at increased actinomycin-D
Discussion concentrations—sufficient to significantly inhibit RNA polymer-
ase II—p53 phosphorylation can also be detected (Ljungman
We have identified an interaction between the ribosomal L11 et al., 2001). These results indicate that nucleolar stress results
protein and HDM2, with evidence that this interaction is en- in the stabilization of p53 through a novel pathway, potentially
hanced in response to inhibition of RNA polymerase I and can involving the activation of the HDM2/L11 interaction. Several
lead to the stabilization and activation of p53. Overall, the effect stress signals, including lack of nutrients (Maden et al., 1969),
of L11 on HDM2 function shows some similarities to the pre- reduced protein synthesis (Pederson and Kumar, 1971), drugs
viously described activities of ARF, which also binds to the (Snyder et al., 1971), and induction of Arf (Sugimoto et al., 2003),
central region of HDM2, inactivating HDM2 function and induc- can lead to changes in ribosomal biogenesis and result in the
inhibition of proliferation. The importance of p53 in the responseing a p53 response. Our results suggest that there may be
several proteins that bind to HDM2 to regulate HDM2 and p53 to these stress signals was recently highlighted by a study show-
ing that this cell cycle arrest is not the direct result of ribosomefunction in response to disparate stress signals.
In bacteria, L11 protein is an rRNA binding protein that has depletion, but rather a response to the activation of p53 (Pestov
et al., 2001). It is possible that perturbations in rRNA synthesisbeen shown to play an important role in the ribosome, being
involved in several steps in protein synthesis. In both bacteria or ribosome assembly results in the release of an excess of free
L11—which is normally a critical part of the 60S ribosomaland plant cells, L11 has also been shown to participate in stress
response pathways (Handa et al., 2001; Zhang et al., 2001), subunit (Kressler et al., 1999)—to allow HDM2/L11 binding. Al-
ternatively (or additionally), stress-induced posttranslationaland other ribosomal proteins exhibit apoptotic activities in mam-
malian cells (Chen and Ioannou, 1999). Our results suggest modifications of L11 or HDM2 may play a role in enhancing
the interaction between the two proteins. Furthermore, otherthat in mammalian cells, L11 may be part of a stress response
pathway that can stabilize p53. Previous studies have shown ribosomal components have been shown to bind HDM2 (Mare-
chal et al., 1994), and these may also play a role in the stabiliza-that perturbations in ribosomal biogenesis can result in “nucleo-
lar stress,” leading to the activation of p53 (Pestov et al., 2001), tion of p53. Interestingly, p53 can also directly inhibit RNA poly-
merase I transcription (Zhai and Comai, 2000), suggesting thatand it is possible that L11 plays a role in mediating this response.
Treatment of cells with low levels of actinomycin-D, which would p53 may play a role in both induction and response to changes
in ribosome biogenesis.selectively inhibit RNA polymerase I and so perturb ribosome
biogenesis, can efficiently stabilize p53. We have now shown Examination of the subcellular localization of L11 and HDM2
suggests that L11 can, under some circumstances, direct thethat these levels of actinomycin-D also enhance the interaction
between endogenous HDM2 and L11 and result in colocalization localization of HDM2 to the nucleoli. Under overexpression con-
ditions, the localization of the two proteins clearly depends onof the HDM2 and L11 proteins in the cell. Stabilization of p53
in response to DNA damage or oncogene activation involves the relative ratio of HDM2 to L11—with high L11 concentrations
being required for nucleolar localization of both proteins. Inpathways that lead to p53 phosphoryation or ARF activation
(Ryan et al., 2001). Interestingly, however, the ability of low unstressed cells, the endogenous proteins do not obviously
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Yeast containing interacting proteins were selected on medium lacking leu-colocalize since L11 is primarily a nucleolar protein and HDM2
cine, tryptophan, and histidine, and selected colonies confirmed by assayingis localized to the nucleoplasm. Nevertheless, many nucleolar
for -galactosidase activity. Positive clones were regrown and DNA fromproteins have been shown to cycle rapidly between the nucleo-
single colonies used as a template for PCR amplification using pGAD424-plasm and nucleolus in unstressed cells (Chen and Huang,
specific primers (Clontech). The amplified fragments were then subcloned
2001), and this shuttling has been suggested to play a role in into the TA cloning vector pCR3.1 (Invitrogen) and sequenced using the T7
the regulation of the interaction between nucleolar proteins and primer. Two inserts examined in this way encoded the human ribosomal
their predominantly nucleoplasmic modifiers (Leary and Huang, L11 protein, one containing the full L11 coding sequence while the other
2001). Potentially, both L11 and HDM2 are cycling rapidly be- encoded an L11 protein deleted of the first ten amino acids.
The insert encoding full-length L11 was then subcloned with antween nucleolus and nucleoplasm in unstressed cells, but since
N-terminal Flag-tag and Kozak box into pCDNA3.1 (Invitrogen) using theour experiments examine only single time points, they may not
PCR strategy previously described (Bates et al., 1998). For this, the forwardreveal a dynamic colocalization of a subfraction of L11 and
primer used was GATCAAGCTTGCACCATGGACTACAAGGACGACGATGAHDM2, which could play a role in determining levels of p53
CAAGGCGCAGGATCAAGGTGAA and the reverse primer GATCGAATTCTTin response to fluctuations in growth conditions. However, in ATTTGCCAGGAAGGATGATCC.
response to nucleolar stress induced by low levels of actinomy- Plasmids were verified by sequencing. Plasmids encoding human wild-
cin-D, the activation HDM2/L11 binding is mirrored by the colo- type p53, Flag-p53, wild-type HDM2, HDM2 1-440, HDM2222-437, HDM2
calization of the two proteins with B23, either in the nucleolus Ala 464, and p14ARF have been described previously (Chen et al., 1995;
Marston et al., 1994; Stott et al., 1998). The HDM2 internal deletion mutantsor in the nucleoplasm. These results are also concordant with
were generated using the ExSite PCR-based site-directed mutagenesis kitour previous observations that low levels of actinomycin-D can
(Stratagene).drive relocalization of endogenous HDM2 to subnuclear struc-
tures containing B23 (Ashcroft et al., 2000). Interestingly, actino-
Cell culturemycin-D-induced changes in the nucleolar-nucleoplasm ex-
Wild-type p53 expressing human U2OS and RKO cells, and p53/Mdm2 null
change rate have been described for other nucleolar proteins mouse embryo fibroblasts, were maintained in Dulbecco modified Eagle
(Chen and Huang, 2001), and it is possible that in addition to medium supplemented with 10% fetal calf serum. Untransformed human
the release of L11 from ribosomal subunits as suggested above, retinal pigment epithelial (RPE) cells were grown in DMEM:F12 medium
stress-induced changes in the rate of shuttling of L11 or HDM2 supplemented with 10% fetal calf serum at 37C, as described by Clontech.
Cells were transfected using calcium phosphate coprecipitation and har-could contribute to the enhanced interaction between the two
vested for protein analysis 24 hr posttransfection. Where appropriate, 1 gproteins. Finally, it is possible that L11 also plays a role in
of pEGFP-N1 (Clontech) was included in each transfection to monitor forstabilizing p53 in response to signals other than nucleolar stress.
equal transfection efficiency and protein loading.Although ARF has been shown to contribute to the stabilization
of p53 in response to the activation of oncogenes such as Myc
In vitro translation
and E2F1, p53 stabilization can occur in response to these In vitro translations of L11 and HDM2 were carried out in rabbit reticulocyte
signals in the absence of ARF, and might reflect a contribution lysates using the TNT coupled reticulocyte lysates system (Promega). To
of L11. In the cell systems studied so far, we were unable to test the role of RNA in the HDM2/L11 interaction, lysates were treated with
detect a reproducible increase in L11 expression or HDM2/ 500 g/ml RNase for 30 min prior to immunoprecipitation.
L11 binding in response to either direct activation of E2F1 or
Protein analysisderegulated proliferation induced by the adenoviral oncogene
Rabbit polyclonal antiserum was raised against a C-terminal peptide ofE1A (data not shown). However, studies showing that members
human L11, corresponding to amino acids 156–170 (RISKEEAMRWFQQKY).of the Myc family can elevate expression of nucleolar proteins,
The specificity of the antibody was tested by Western blot detection ofincluding L11 (Boon et al., 2001) and Bop1 (Shiio et al., 2002),
overexpressed Flag-L11, and by detection of Flag-L11 proteins immunopre-suggest that L11 may also play a role in mediating the induction
cipitated with the L11 antiserum and then Western blotted for Flag or L11.
of p53 in response to Myc. To assess L11, HDM2, or p53 protein levels, proteins from whole-cell
Our results highlight the functional similarities between L11 extracts were separated by SDS 12% polyacrylamide gel electrophoresis
and ARF in their interaction with HDM2 and their ability to induce and analyzed by Western blotting with anti-p53 DO-1 or 1801 (Pharmingen),
the relocalization of HDM2 and activate a p53-dependent cell anti-HDM2 AB1, AB2, and SMP14 (Oncogene Science), anti-Flag (Sigma),
polyclonal anti-L11, and anti-GFP (Clontech) antibodies.cycle arrest. These studies reveal a mechanism for the inhibition
To assay for association between HDM2 and p53 or L11, cells wereof HDM2 and activation of p53 through interaction with L11.
washed three times in ice-cold PBS and lysed in 500 l (per 10 cm diameterThis mechanism to stabilize p53 may play a role in the response
dish) of NP40 lysis buffer (100 mM NaCl, 100 mM Tris [pH 8.0], 1% NP40)to abnormalities in ribosomal biogenesis induced by abnormal
for 30 min at 4C. p53 protein was immunoprecipitated overnight at 4C by
metabolic conditions that could occur during tumor develop- incubation with a mixture of anti-p53 protein A Sepharose beads equilibrated
ment. Mutations in HDM2 that perturb this response pathway in NP40 lysis buffer, Flag-L11 by incubation with a mixture of anti-Flag protein
by preventing the HDM2/L11 interaction may therefore contrib- A Sepharose beads equilibrated in NP40 lysis buffer, and endogenous L11
ute to cancer development by preventing the activation of p53 by incubation with a mixture of polyclonal anti-L11 protein A Sepharose
beads equilibrated in NP40 lysis buffer. The immunoprecipitated protein wasin response to these types of stress signals. A more complete
washed three times with NP40 buffer, and samples were resuspended inunderstanding of how L11 is activated may reveal novel targets
50 l of 2 SDS sample buffer and incubated at room temperature for 10for the development of therapies aimed at reactivating p53 in
min. The samples were then separated by SDS 12% polyacrylamide gelsome of those cancers that retain a wild-type p53 gene.
electrophoresis and analyzed by Western blotting with anti-Flag or anti-
L11 and anti-HDM2 antibodies. Proteins expressed in vitro were allowedExperimental procedures
to associate on ice for 30 min before dilution in 500 l NP40 buffer and
immunoprecipitation as above. Following polyacrylamide gel electrophore-Plasmids
sis, these 35S-labeled proteins were detected by autoradiography.A yeast two-hybrid screen (Fields and Song, 1989) was carried out to identify
proteins that interact with HDM2. A cDNA fragment of HDM2 encoding
Immunofluorescenceamino acids 210 to 491 was cloned in frame with the DBA binding domain
U2OS cells were plated on dishes containing 1 cm diameter glass coverslipsof Gal4 in pGBT9 (Clontech) and transformed into Y190 yeast (Clontech)
with a human embryonal kidney cDNA library cloned into pGAD (Clontech). and transfected as described. Twenty-four hours after transfection, cells on
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biogenesis cycle between the nucleolus and nucleoplasm in interphase cells.the coverslips were washed three times with phosphate-buffered saline
J. Cell Biol. 153, 169–176.(PBS), and then fixed in 4% paraformaldehyde for 10 min at room tempera-
ture. After fixation, cells were washed in PBS three times and then permeabil- Chen, F.W., and Ioannou, Y.A. (1999). Ribosomal proteins in cell proliferation
ized in ice-cold PBS containing 0.2% Triton X-100 for 5 min. After blocking and apoptosis. Int. Rev. Immunol. 18, 429–448.
in PBS containing 0.5% bovine serum albumin at room temperature for 30
Chen, J., Lin, J., and Levine, A.J. (1995). Regulation of transcription functionsmin, the cells were incubated overnight at 4C with anti-B23 (Santa Cruz)
of the p53 tumor suppressor by the mdm-2 oncogene. Mol. Med. 1, 142–152.or anti-HDM2 AB1 (Oncogene Science) antibody, or for 2 hr at RT with anti-
Flag (Sigma) antibody in blocking solution. Cells were washed three times de Rozieres, S., Maya, R., Oren, M., and Lozano, G. (2000). The loss of
with PBS and incubated for 1 hr at room temperature with fluorescein isothio- mdm2 induces p53 mediated apoptosis. Oncogene 19, 1691–1697.
cyanate (FITC-conjugated rabbit anti-mouse antibody [1:100; Sigma], FITC-
Fakharzadeh, S.S., Trusko, S.P., and George, D.L. (1991). Tumorigenic po-conjugated donkey anti-rabbit antibody [1:100; Amersham], Cy3-conjugated
tential associated with enhanced expression of a gene that is amplified indonkey anti-rabbit antibody [1:500; Jackson ImmunoResearch], Cy3-conju-
a mouse tumor cell line. EMBO J. 10, 1565–1569.gated donkey anti-mouse antibody [1:500; Jackson ImmunoResearch], or
Cy-3 conjugated donkey anti-goat antibody [1:100; Sigma]) in blocking solu- Fang, S., Jensen, J.P., Ludwig, R.L., Vousden, K.H., and Weissman, A.M.
tion, containing 1 g of DAPI (Sigma)/ml. Following three washes with PBS, (2000). Ubiquitin protein ligase activity of Mdm2: differential RING finger
the slides were mounted with PBS/glycerol mount. requirements for ubiquitination and proteasomal targeting of Mdm2 and p53.
J. Biol. Chem. 275, 8945–8951.
Flow cytometry
Fields, S., and Song, O. (1989). A novel genetic system to detect protein-U2OS cells were transfected using calcium phosphate coprecipitation and
protein interactions. Nature 340, 245–246.washed the following day. The cells were then harvested for FACS at the
times indicated in the figure legends. Cells were stained and flow cytometric Geyer, R.K., Yu, Z.K., and Maki, C.G. (2000). The MDM2 RING-finger domain
analysis (FACScalibur, Becton Dickinson) carried out as previously described is required to promote p53 nuclear export. Nat. Cell Biol. 2, 569–573.
(Rowan et al., 1996; Zhu et al., 1993).
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